Lee Tien-Li, CEO of Aardvark Therapeutics ($AARD), made six open market purchases totaling about $359,000 in the past year, with the latest on December 11, 2025. His buying activity ranks 1,049th among 4,983 insiders, below the average purchase of $1.5 million and 3.3 transactions per insider. He reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 9, 2026 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | A | Stock option (right to buy) | 203851 | $0.00 | 203,851.0000 | 21,773,272 | 50.00% | 0.94% |
| Dec. 11, 2025 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | P | Common Stock | 7000 | $14.49 | 3,025,641.0000 | 21,773,272 | 0.23% | 0.03% |
| Oct. 15, 2025 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | M | Common Stock | 1229 | $4.24 | 3,018,641.0000 | 0 | 0.04% | 0.00% |
| Oct. 15, 2025 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | M | Stock option (right to buy) | 1229 | $0.00 | 40,566.0000 | 0 | 2.94% | 0.00% |
| Sept. 15, 2025 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | P | Common Stock | 6500 | $9.51 | 3,013,912.0000 | 0 | 0.22% | 0.00% |
| Sept. 15, 2025 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | P | Common Stock | 3500 | $9.94 | 3,017,412.0000 | 0 | 0.12% | 0.00% |
| Sept. 12, 2025 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | P | Common Stock | 5000 | $8.50 | 3,007,412.0000 | 0 | 0.17% | 0.00% |
| Sept. 11, 2025 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | P | Common Stock | 6000 | $7.82 | 3,002,412.0000 | 0 | 0.20% | 0.00% |
| Sept. 10, 2025 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | P | Common Stock | 9000 | $7.91 | 2,996,412.0000 | 0 | 0.30% | 0.00% |
| Aug. 28, 2025 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | M | Common Stock | 17209 | $4.24 | 2,987,412.0000 | 0 | 0.58% | 0.00% |
| Aug. 28, 2025 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | M | Stock option (right to buy) | 17209 | $0.00 | 41,795.0000 | 0 | 29.17% | 0.00% |
| June 11, 2025 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | A | Stock option (right to buy) | 549534 | $0.00 | 549,534.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2025 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | C | Series A Convertible Preferred Stock | 350002 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 14, 2025 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | P | Common Stock | 16542 | $16.00 | 2,970,203.0000 | 0 | 0.56% | 0.00% |
| Feb. 14, 2025 | Aardvark Therapeutics, Inc. | $AARD | Lee Tien-Li | Chief Executive Officer | C | Common Stock | 41303 | $0.00 | 2,953,661.0000 | 0 | 1.42% | 0.00% |